Feed RNAZ
RN

TransCode Therapeutics, Inc.

RNAZ · NASDAQ

$1.76 +1.15% (+$0.02)
1M -34.81%
Market Cap $1.86M
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$2.14

21.6% upside

Trenutna cena

$1.76

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica RNAZ trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
0/9
Valuation
-
N/A
P/FCF N/A
P/E N/A
EV/FFO N/A
Growth
100 /100
Growing
Book val. growth 47.20%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A
Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
2 /100
Poor
Asset turnover 0.00x
ROIC 0.18%
ROA 0.03%
Debt
42 /100
Moderate
Int. coverage -6,516.48x
Current ratio 1.97x
Debt/Assets N/A
Stability
25 /100
Unstable
Profitable years 0
Beta 1.17x
EPS volatility 161.70%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RNAZ
Online

O podjetju

TransCode Therapeutics, Inc. is a biotechnology company that focuses on developing therapeutic products based on RNA. The company employs advanced technologies to modify and optimize RNA in order to create drugs for various diseases. Their research centers on utilizing RNA therapy to influence gene expression and provide novel approaches to treating various health conditions. TransCode Therapeutics aims to bring innovative treatment options and contribute to advancements in the field of biotechnology and therapeutic strategies. Investors interested in advancements in biotechnology and RNA therapy might see potential in TransCode Therapeutics, Inc. shares for innovation and growth in this field.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Philippe Calais

Employees

12

Headquarters

Boston

Prihajajoči dogodki

18 NOV.

Earnings

Upcoming earnings report

57d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.